Infused L-histidinol and cisplatin: schedule, specificity, and proliferation dependence.
The dose and schedule requirements found for the combination of L-histidinol and 5-fluorouracil (5-FU) were concordant with those for the combination of L-histidinol and cisplatin. Furthermore, cisplatin-L-histidinol was active against colon 26 tumor, an adenocarcinoma that developed in a BALB/c female mouse and that has been grown as a solid tumor. The toxicity of cisplatin was prevented only when cisplatin was given before L-histidinol. Studies of L-histidinol and 5-FU had similar results. For (DBA/2 X BALB/c)F1 mice, 50 mg of L-histidinol per mouse was required for protection; for hematopoietic precursor cells, protection was dependent on the dose of L-histidinol. In contrast, both L1210 leukemia cells and colon 26 adenocarcinoma cells were more efficiently killed by combinations of L-histidinol and cisplatin. This effect depended on the doses of L-histidinol and cisplatin, a finding similar to the finding for hematopoietic precursor cells.
Edelstein
M B
MB
Section of Hematology and Oncology, Veterans Administration Medical Center, Allen Park, MI 48101.
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use* / Q000633:toxicity; D002455:Cell Division / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002945:Cisplatin / Q000008:administration & dosage; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003114:Colony-Forming Units Assay; D004305:Dose-Response Relationship, Drug; D006412:Hematopoietic Stem Cells / Q000187:drug effects; D006641:Histidinol / Q000008:administration & dosage; D007939:Leukemia L1210 / Q000188:drug therapy*; D051379:Mice; D008815:Mice, Inbred Strains
D006641:Histidinol; D002945:Cisplatin